Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Rinaldi I., Putri A., Louisa M., Koesnoe S.
23475122400;57214826648;41461551400;26028015000;
High stat5a expression is associated with major molecular response achievement failure of chronic phase chronic myeloid leukemia patients receiving hydroxyurea before imatinib: A cross-sectional study
2021
Open Access Macedonian Journal of Medical Sciences
9
1160
1167
Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Division of Allergy and Clinical Immunology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
Rinaldi, I., Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Putri, A., Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Koesnoe, S., Department of Internal Medicine, Division of Allergy and Clinical Immunology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
BACKGROUND: STAT5 is a transcriptional factor which when highly expressed in chronic myeloid leukemia (CML) cells stimulate proliferation and mediate resistance from tyrosine kinase inhibitors, resulting in major molecular response (MMR) failure. STAT5 has two isoforms, STAT5A and STAT5B. However, prolonged use of imatinib appears to only upregulate STAT5A pathway. In addition, the resistance conferred by STAT5A does not extend to other drugs such as hydroxyurea. Hence, STAT5A and STAT5B might have different functions in CML cells. AIM: The objective of the study was to determine the association of STAT5A and STAT5B expression with MMR failure in CML patients. METHODS: This was a cross-sectional study of CML patients in chronic phase with age ? 18 years old, receiving IM therapy ? 12 months, and previously given hydroxyurea. MMR status was evaluated and patients were categorized as achieved or failed to achieve MMR. Expression levels of STAT5A and STAT5B were conducted using RT-PCR methods. Associations between STAT5A expression, STAT5B expression, hydroxyurea duration, and imatinib duration with MMR achievement were calculated using logistic regression. RESULTS: A total of 118 patients were analyzed; 71.1% failed to achieve MMR. Multivariate logistic regression analysis showed statistically significant association between high STAT5A expression (odds ratio [OR]: 3.852; 95% confidence interval [CI]: 1.420?10.452; p = 0.008), STAT5A/STAT5B interaction (OR: 0.150; 95% CI: 0.038?0.593; p = 0.007), longer hydroxyurea administration (OR: 3.882; 95% CI: 1.023?14.733; p = 0.046), and shorter imatinib administration (OR: 0.333; 95% CI: 0.132?0.840; p = 0.020) with MMR achievement failure. After adjusting STAT5A expression with STAT5A/STAT5B interaction, high STAT5A expression independently increased the likelihood of MMR achievement failure only in high expression STAT5B patients (OR: 3.852; 95% CI: 1.420?10.452; p = 0.008). CONCLUSION: High STAT5A expression which is induced by high STAT5B is associated with MMR achievement failure of chronic phase CML patients who received hydroxyurea before imatinib. Longer duration of hydroxyurea and shorter duration of IM confound of STAT5A expression to MMR achievement failure. ? 2021 Ikhwan Rinaldi, Anastasia Putri, Melva Louisa, Sukamto Koesnoe.
Breakpoint cluster region-ABL; Chronic myeloid leukemia; Imatinib; STAT5A; STAT5B
Scientific Foundation SPIROSKI
18579655
Article
Q3
288
15252